For drugmakers with production in China, the manufacturing problems created by the COVID-19 outbreak are only part of the difficulty.…More

When the year started, many pharma and political experts believed the industry would face intense pricing scrutiny throughout the year, and possibly reforms. But…More

Amid Amgen’s pricing war with Sanofi and Regeneron’s Praluent, PCSK9 cholesterol fighter Repatha has been looking for a leg up in a wide-ranging clinical…More

In an unusual display of coordinated frankness for the industry, a coalition representing generic drug makers, insurers, pharmacies and benefit…More

The specter of global drug shortages looms large amid the coronavirus pandemic. But so far, the supply chain is holding…More

ASCO attendees, you can cancel the ultra-pricey hotel reservations, close your browser tabs on that Chicago restaurant research and let…More

India, like other countries, has grown dependent on cheap active pharmaceutical ingredients from China. With the COVID-19 outbreak having put…More

For years, drug pricing has been a top issue of focus for politicians and Americans. But amid the COVID-19 pandemic, legislation on the…More

Pfizer has set out on a costly quest to improve on its blockbuster Prevnar 13 and capture the next-gen pneumococcal vaccine market. Now,…More